Diagnosing Epilepsy & Seizure Disorders | NYU Langone Health
NYU Langone specialists use exams and imaging tests to diagnose epilepsy and seizure disorders.
Sports Medicine Center | NYU Langone Health
Orthopedic surgeons and sports medicine doctors at NYU Langone’s Sports Medicine Center treat athletic, overuse, and everyday injuries.
A Phase 1 Trial Investigating LY4101174 an Antibody-Drug Conjugate Targeting Nectin-4 in Participants with Recurrent Advanced or Metastatic Solid Tumors
This is a study looking at a new medicine called LY4101174. The study team wants to see if it has few effects and how well it works in treating the cancer in patients with advanced or metastatic cancers, including urothelial carcinoma. The study has two parts. In the first part, the study team will test different amounts of LY4101174 to find the dose with the fewest side effects for the next part of the study. The study team will also check if there is a need to adjust the dose based on side effects if there are any. The second part will involve more patients, and they will use the best dose with few side effects found in the first part. The study will focus on different types of cancers like breast, lung, ovarian, and other cancers. The study team wants to understand how this medicine works and if it helps patients with treating these cancers.
Child Study Center | NYU Langone Health
The Child Study Center, part of Hassenfeld Children’s Hospital at NYU Langone, treats children with mental health and developmental conditions.
Diagnosing Epilepsy & Seizure Disorders in Children | NYU Langone Health
Experts at Hassenfeld Children’s Hospital at NYU Langone use exams, tests, and EEG to diagnose epilepsy and seizure disorders.
A Phase 1 First in Human Study of ARV-393 in Adult Participants with Advanced Non-Hodgkin s Lymphoma
This is a multicenter, open-label Phase 1 study testing a new drug called ARV-393 in adults with advanced non-Hodgkin lymphoma (NHL). The study will look at the side effects of the drug, how well it works, and how the body processes it. Initially, the focus will be on ARV-393 by itself. To find the best dose, the study will group patients into sets of three. The goal is to find a dose that causes side effects in about 25% of patients. Doctors will decide whether to increase or decrease the dose based on the side effects and other information. There will be a waiting period of at least 24 hours between giving the first dose to the first patient in a group and the next doses. If the first patient does not have any side effects, more patients can receive that dose. If there are too many side effects, the dose will be lowered. Each dose level will include a small number of patients who will be closely monitored. If the rate of side effects is lower than the target, the dose can be increased; if it is higher than the target, the dose will be lowered. The study will stop if there are serious concerns about the side effects at any dose. When the dose escalation is finished, the best dose will be the one that results in the side effect rate closest to 25%.
Center for Blood Cancers | NYU Langone Health
Experts at the Center for Blood Cancers, part of Perlmutter Cancer Center, treat blood cancers such as leukemia, lymphoma, and multiple myeloma.
Pediatric Congenital Heart Program | NYU Langone Health
The Pediatric Congenital Heart Program at Hassenfeld Children’s Hospital offers innovative care for people with congenital heart conditions.
Leveraging Biomarkers for Personalized Treatment of Alcohol Use Disorder Comorbid With PTSD
The proposed study is a double-blind, 2-group randomized controlled trial designed to contrast acute and persisting effects of topiramate to those of placebo treatment in a sample of 150 participants with moderate to severe AUD comorbid with PTSD/subthreshold PTSD, and to evaluate the moderating effect of rs2832407 genotype on medication effects. Participants will be randomized in a 2:1 ratio to topiramate vs. placebo. Drug will be titrated to a maximum dose of 200 mg over 8 weeks, continued for 4 more weeks for a total of 12 weeks of treatment, and tapered over a 2-week period. We propose an integrative translational focus on alterations in excitatory and inhibitory signaling, focusing on GABA and glutamate and related circuitry, to model the neurobiology of AUD comorbid with PTSD/subthreshold PTSD and the mitigating effects of topiramate. We will study the behavioral, genetic, and plasma biomarker effects of topiramate vs. placebo in 150 participants with co-occurring AUD and PTSD/subthreshold and ascertain multi-modal imaging markers including structural MRI, task-based fMRI, and TMS evoked potentials in EEG. Imaging markers will be used to characterize excitatory and inhibitory circuits in the clinical trial participants with AUD+PTSD/subthreshold to determine predictors and mechanisms of topiramate vs. placebo treatment outcomes. Clinical interviews will be audio- taped to ensure clinical adherence and conduct interrater reliability. De-identified audio recordings of participants who consent to participate in the voicemarkers analysis will be encrypted and sent via secure sites for analysis. This project will advance our knowledge of personalized medicine for AUD comorbid with PTSD/subthreshold, with particular emphasis on understanding the mechanisms that account for the high variability in treatment outcomes for this comorbidity, how treatments like TPM are effective for certain individuals, and how best to identify those most likely to respond to TPM.
THE PROSPECTIVE NATURAL HISTORY OF FAMILIAL DYSAUTONOMIA
Our ultimate goal is to develop new treatments for patients with familial dysautonomia (FD, OMIM 223900). We also want to learn which specific nerve populations are affected by the disease-causing mutation, whether these features are progressive, and how best to measure them in clinical trials. FD is caused by a founder mutation in the IKBKAP gene that is carried by 1:30 people of European Jewish ancestry. Over 99% of affected patients have two copies of the identical founder mutation. This affects the development of the sensory nervous system, which relays information to the brain. FD is both developmental and progressive. Current drug treatments are supportive and none specifically target the on-going neurological decline. Partnership between academic centers, advocacy groups and federal agencies has allowed the creation of a pipeline for drug development and an infrastructure for translational research. The first aim of this project will be to enroll patients with FD from around the world in a non-interventional natural history study. We will score the severity of their clinical features and follow how they evolve over time. The natural history will focus on establishing disease-specific milestones to use as outcome measures in future clinical trials. We will find ways to measure the progressive neurological aspects of the disease including blindness and gait ataxia, which are intrinsically related and most devastating to the patient’s quality of life overtime. We will also explore other potential biomarkers that quantify renal, cardiovascular, respiratory, orthopedic and cognitive aspects of the disease, which will help us monitor adverse events. The second aim of this project will address one of the most intriguing questions about the disease; why some patients are more severely affected than others. The study will include genomic sequencing from patients with FD, to find specific modifier genes that influence the severity of traits as possible targets for future drug development. Some of these genes may be important in the general population, but discovering them could be easier in FD patients due to >99% being homozygous for the founder mutation.